NAPLEX Quiz: Risk Management And Error Prevention

What this quiz covers

This quiz focuses on Risk Management And Error Prevention, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Dispense the 10 mg/mL vial and instruct the nurse to measure the dose carefully at the bedside
2. Prepare and dispense a patient-specific, pharmacy-diluted syringe (standard concentration) with barcode labeling and require an independent double-check prior to administration (correct answer)
3. Recommend intramuscular administration to reduce need for dilution
4. Change the order to hydromorphone because it is less likely to cause dosing errors

Explanation: This question addresses pediatric high-alert medication safety and the risks of using adult-concentration products in children. The key risk factors are the small pediatric dose (1 mg for a 20 kg child), the high concentration of adult morphine vials (10 mg/mL), and the potential for 10-fold dosing errors. Option B is the BEST approach because pharmacy-prepared, patient-specific syringes with appropriate dilution eliminate bedside calculation errors, barcode scanning ensures correct patient matching, and independent double-checks catch preparation errors before they reach the patient. Option A is dangerous because expecting nurses to accurately measure 0.1 mL from a concentrated vial invites calculation and measurement errors. Option C is inappropriate because morphine must be given IV as ordered for acute pain control, and route changes require prescriber authorization. Option D doesn't address the immediate safety concern and unnecessarily delays pain management. The transferable safety principle is that pediatric doses of high-alert medications should be prepared in the pharmacy using standardized concentrations and volumes that minimize bedside manipulation, with technology and independent verification providing additional safety layers.

Question 2

1. Repeat INR within 2–3 days of starting TMP-SMX and again after completion, with warfarin dose adjustment as needed (correct answer)
2. Monitor A1c in 3 months because antibiotics can affect glucose control
3. Monitor serum potassium only at the end of therapy and do not reassess INR
4. Monitor AST/ALT weekly because warfarin primarily causes hepatotoxicity

Explanation: This question tests knowledge of clinically significant drug interactions requiring enhanced monitoring. The critical risk is that trimethoprim-sulfamethoxazole significantly inhibits warfarin metabolism, typically increasing INR and bleeding risk within 2-3 days of starting therapy. Option A is the BEST monitoring approach because it captures the peak interaction effect with early INR monitoring and ensures safe warfarin management throughout and after antibiotic therapy. Option B is irrelevant because A1c reflects long-term glucose control and isn't acutely affected by short-term antibiotic use. Option C is inadequate because waiting until therapy completion misses the critical window when INR elevation occurs, and ignoring INR monitoring could result in serious bleeding. Option D is incorrect because warfarin's primary concern is bleeding risk, not hepatotoxicity, and weekly LFT monitoring isn't indicated for this interaction. The clinical pearl is that TMP-SMX is one of the most significant warfarin interactions, often requiring empiric warfarin dose reduction of 25-50% and close INR monitoring within 2-3 days of initiation to prevent supratherapeutic anticoagulation and bleeding complications.

Question 3

1. Continue both tiotropium and scheduled ipratropium/albuterol to maximize bronchodilation without clarification
2. Clarify intended prednisone dose/duration and inhaled regimen with the discharging team, then communicate a single, updated medication list to the SNF (correct answer)
3. Stop all inhalers and use only nebulizers because they are easier at SNF
4. Assume the SNF list is correct because it is the most recent document and ignore the discharge list

Explanation: This question tests reconciliation at care transitions to prevent therapy discrepancies. The key risk element is conflicting prednisone and bronchodilator orders, risking steroid overuse or anticholinergic duplication in a COPD patient. Clarifying with the team and providing an updated list is the best choice as it resolves ambiguities for safe continuation. Continuing duplicates or assuming one list's superiority perpetuates errors, while stopping inhalers ignores efficacy. Converting to nebulizers without reason is suboptimal. A pearl is to verify intents in transitions for chronic therapies. Pharmacists should use a reconciliation framework to ensure continuity and safety.

Question 4

1. Allow either concentration to be used as long as the infusion rate is double-checked by the nurse at the bedside
2. Standardize to a single heparin infusion concentration on the unit and require independent double-check of concentration and pump programming before starting (correct answer)
3. Convert to subcutaneous heparin without confirming the indication to avoid infusion errors
4. Rely on the prescriber's order entry to prevent concentration selection errors and dispense both concentrations

Explanation: This question tests the concept of standardizing concentrations for high-alert medications to prevent infusion errors. The key risk element is the availability of two heparin concentrations on the unit, which could lead to a 2-fold dosing error in a patient requiring therapeutic anticoagulation for atrial fibrillation. Standardizing to a single concentration and requiring independent double-checks is the best choice because it minimizes selection errors and ensures accurate pump programming through verification. Allowing either concentration with only nurse double-checks is suboptimal as it maintains the risk of mix-up without systemic prevention, while converting to subcutaneous heparin ignores the indication and could compromise efficacy. Relying solely on prescriber orders or dispensing both perpetuates the error potential without safeguards. A key clinical pearl is that for high-alert infusions like heparin, standardization and double-checks are essential to reduce variability and harm. Pharmacists should advocate for protocol-driven approaches in risk management to enhance patient safety across settings.

Question 5

1. Serum digoxin concentration and clinical signs (e.g., bradycardia, nausea, visual changes), with renal function and electrolytes monitored (correct answer)
2. INR monitoring because digoxin increases bleeding risk
3. A1c monitoring because macrolides worsen diabetes control
4. Serum uric acid because clarithromycin increases gout risk

Explanation: This question tests monitoring for drug interactions causing toxicity. The key risk element is clarithromycin-digoxin interaction with renal impairment, increasing toxicity risk in an atrial fibrillation patient. Digoxin levels and clinical signs with renal/electrolyte monitoring is the best choice as it detects issues early. INR, A1c, or uric acid monitoring is unrelated. Assuming bleeding or other risks overlooks primary concerns. A clinical pearl is to monitor levels for narrow-index drugs in interactions. Pharmacists should apply targeted surveillance frameworks for safety.

Question 6

1. Standardize to a single norepinephrine concentration for adult infusions when possible and require independent double-check of concentration and pump programming (correct answer)
2. Allow nurses to mix norepinephrine at bedside to reduce pharmacy workload
3. Label both concentrations identically so staff focus on the infusion rate rather than the bag
4. Avoid smart pumps for vasopressors because dose titration needs flexibility

Explanation: This question tests standardization for high-alert vasopressor infusions to prevent concentration errors. The key risk element is dual norepinephrine concentrations, risking hemodynamic instability in a septic shock patient. Standardizing to one concentration with double-checks is the best choice as it reduces variability and errors. Allowing bedside mixing or identical labeling increases risks, while avoiding pumps limits safety features. Focusing on rate alone ignores concentration. A pearl is that standardization minimizes high-alert infusion errors. Pharmacists should promote protocols with verifications for critical meds.

Question 7

1. Implement weekly-only order sentences with hard-stop alerts for daily methotrexate (non-oncologic use) and require pharmacist verification of indication and frequency (correct answer)
2. Allow daily dosing and monitor for mouth sores to detect toxicity early
3. Change the dose to 1 mg daily to approximate the weekly dose without prescriber input
4. Dispense as daily and instruct nursing to hold on weekends to reduce exposure

Explanation: This question tests order entry safeguards for high-alert drugs like methotrexate to prevent frequency errors. The key risk element is daily instead of weekly dosing, causing toxicity in a rheumatoid arthritis patient on immunosuppressants. Implementing weekly-only orders with alerts and verification is the best choice as it blocks errors systemically. Allowing daily with monitoring or altering without input perpetuates risks, while instructing holds is unreliable. Changing dose independently violates protocols. A pearl is that high-alert drugs need hard-stop controls. Pharmacists should advocate for CPOE safeguards in risk management.

Question 8

1. Advise the patient to stop warfarin for 7 days without contacting the prescriber
2. Recommend switching to rivaroxaban immediately because it has fewer interactions in mechanical valves
3. Contact the prescriber to consider an alternative antibiotic and/or empiric warfarin dose adjustment, and arrange an earlier INR check within 2–3 days (correct answer)
4. Monitor A1c in 1 week because antibiotics can affect glucose and indirectly change INR

Explanation: This question tests management of drug interactions in anticoagulation to prevent bleeding. The key risk element is the warfarin-trimethoprim/sulfamethoxazole interaction elevating INR in a patient with mechanical valve and amiodarone. Contacting the prescriber for alternatives and early INR check is the best choice as it proactively mitigates risk. Stopping warfarin or switching to rivaroxaban without input is unsafe, especially in valves, while monitoring A1c is irrelevant. Assuming no action risks hemorrhage. A clinical pearl is to anticipate interactions with high-risk drugs like warfarin. Pharmacists should use a framework of alert, communicate, and monitor for interaction management.

Question 9

1. Prepare the suspension by estimation and label it as "shake well" without documenting calculations
2. Use a validated master formulation record, perform and document calculations and a second-person verification of final concentration and volume before dispensing (correct answer)
3. Substitute alprazolam tablets in the suspension because they are easier to crush
4. Skip beyond-use dating to avoid delaying therapy and allow use until the bottle is empty

Explanation: This question tests quality assurance in non-sterile compounding to prevent concentration errors. The key risk element is the potential for miscalculation in preparing clonazepam suspension for tube administration, leading to dosing inaccuracies in a patient with seizure risk. Using a validated formula with documented calculations and second-person verification is the best choice as it ensures accuracy and compliance with USP standards. Estimating without documentation risks errors, while substituting tablets or skipping dating compromises safety and stability. Using unvalidated methods invites under- or overdosing. A pearl is that compounding requires rigorous verification to mitigate calculation risks. Pharmacists should apply a framework of standardization, double-checks, and documentation for safe compounding practices.

Question 10

1. Refill early if the patient signs a statement promising safe use
2. Check the PDMP, follow pharmacy policy for early fills (including prescriber contact and documentation), and assess for unsafe duplicate sedatives before dispensing (correct answer)
3. Transfer the prescription to another pharmacy without notifying the prescriber to avoid conflict
4. Increase the quantity dispensed to reduce the number of monthly pharmacy visits

Explanation: This question tests policies for early refills of controlled substances to prevent misuse. The key risk element is repeated early alprazolam requests in a patient on multiple sedatives, raising diversion and overdose concerns. Checking PDMP, following policy with prescriber contact, and assessing duplicates is the best choice as it upholds corresponding responsibility. Refilling with a promise or increasing quantity enables misuse, while transferring or refusing without review violates protocols. Ignoring documentation risks non-compliance. A clinical pearl is to evaluate patterns and combinations in controlled substance requests. Pharmacists should use a framework of PDMP review, verification, and documentation for safe dispensing decisions.

Question 11

1. Dispense apixaban and advise the patient to continue warfarin until the first follow-up visit to avoid clot risk
2. Hold dispensing apixaban until the INR is < 1.5 because all DOAC starts require a low INR
3. Clarify with the discharging provider whether warfarin was intended to be stopped and document discontinuation before dispensing apixaban (correct answer)
4. Recommend adding aspirin 81 mg daily for additional stroke prevention while on apixaban

Explanation: This question tests medication reconciliation at transitions of care to prevent duplicate therapy errors. The key risk element is the potential continuation of warfarin alongside new apixaban, leading to excessive anticoagulation and bleeding risk in an elderly patient post-pneumonia. Clarifying with the provider and documenting discontinuation is the best choice as it ensures intentional therapy changes and accurate reconciliation. Dispensing apixaban while continuing warfarin risks over-anticoagulation, and holding until INR <1.5 is incorrect as apixaban initiation doesn't require low INR unless bridging. Adding aspirin or assuming continuation without verification overlooks bleeding risks and reconciliation principles. A transferable pearl is to always verify therapy intent during reconciliation, especially with high-risk drugs like anticoagulants. Pharmacists should use a systematic framework: compare lists, clarify discrepancies, and document to prevent errors at care transitions.

Question 12

1. Require indication-based verification and barcode/NDC match at dispensing, with tall-man lettering alerts for Lamictal vs Lamisil (correct answer)
2. Dispense the entered product and instruct the patient to call if it looks unfamiliar
3. Remove both drugs from the formulary to avoid confusion
4. Assume the higher dose (250 mg) is correct because titration packs are uncommon

Explanation: This question tests prevention of LASA errors in prescription processing. The key risk element is the similarity between Lamictal and Lamisil, leading to inappropriate therapy in a patient needing seizure control. Requiring indication verification and barcode checks with tall-man alerts is the best choice as it catches errors at entry and dispensing. Dispensing based on insurance or patient assumption is unreliable, while removing drugs or bypassing checks increases risks. Assuming dose correctness overlooks LASA issues. A pearl is that LASA mitigation relies on alerts and verifications. Pharmacists should integrate multi-step checks into workflows for error prevention.

Question 13

1. Continue both clopidogrel and prasugrel temporarily to ensure antiplatelet coverage
2. Discontinue all antiplatelets until cardiology rounds to avoid bleeding
3. Verify the intended P2Y12 inhibitor and indication (e.g., recent PCI) using patient interview, prior records, and prescriber confirmation, then document the correct agent (correct answer)
4. Automatically substitute prasugrel for clopidogrel because it is more potent

Explanation: This question tests medication reconciliation to resolve discrepancies in high-risk therapies like antiplatelets. The key risk element is the conflicting clopidogrel and prasugrel listings, potentially leading to bleeding or thrombosis in a CAD patient post-PCI. Verifying the intended agent via multiple sources and documenting is the best choice as it ensures accurate therapy continuation. Continuing both risks bleeding, while discontinuing all or automatic substitution ignores indication and safety. Assuming potency without verification is erroneous. A pearl is to cross-verify sources in reconciliation for high-risk drugs. Pharmacists should employ a systematic approach: gather data, clarify, and document to prevent transition errors.

Question 14

1. Daily serum potassium to monitor for hyperkalemia from vancomycin
2. Vancomycin AUC-guided monitoring (or troughs per protocol) along with serial SCr/urine output to adjust dosing (correct answer)
3. INR every 48 hours to monitor for anticoagulation changes from vancomycin
4. Hemoglobin A1c weekly to assess glycemic control while on antibiotics

Explanation: This question tests monitoring for high-risk medications to prevent adverse events like nephrotoxicity. The key risk element is vancomycin use in an elderly patient with baseline renal impairment, increasing toxicity risk without proper dosing adjustments. AUC-guided monitoring with serial SCr and urine output is the best choice as it allows timely dose adjustments to prevent kidney injury. Daily potassium monitoring targets the wrong risk, as hyperkalemia isn't primary with vancomycin, while INR or A1c checks are irrelevant here. Focusing on unrelated labs overlooks nephrotoxicity. A clinical pearl is to prioritize drug-specific monitoring parameters for high-risk agents like vancomycin. Pharmacists should use a framework of baseline assessment, ongoing surveillance, and adjustment to manage risks effectively.

Question 15

1. Require pharmacist verification of weight-based dose and smart-pump drug library use with independent double-check before starting the infusion (correct answer)
2. Allow free-text infusion programming because pediatric doses vary widely
3. Round the dose down to 1 unit/hour without documenting to reduce hypoglycemia risk
4. Delay insulin infusion until A1c is repeated to confirm chronic hyperglycemia

Explanation: This question tests safeguards for pediatric high-alert medication infusions to prevent dosing errors. The key risk element is the weight-based insulin order in a child with DKA, where misprogramming could cause severe hypoglycemia if units/hour is mistaken for units/kg/hour. Requiring pharmacist verification and smart-pump use with double-checks is the best choice as it ensures accurate calculation and administration. Allowing free-text programming increases error risk, while rounding down or delaying ignores clinical needs. Substituting without protocol is unsafe. A clinical pearl is that weight-based dosing in pediatrics demands multiple verifications. Pharmacists should use a framework of technology and human checks to prevent high-alert errors in vulnerable populations.

Question 16

1. Dispense as written and advise the patient to stop if any rash occurs
2. Contact the prescriber to verify appropriate lamotrigine titration for use with valproic acid before dispensing and document the intervention (correct answer)
3. Automatically substitute carbamazepine to avoid rash risk without prescriber involvement
4. Recommend taking lamotrigine with food to prevent rash and proceed with dispensing

Explanation: This question evaluates prevention of serious adverse drug reactions through proper drug interaction management and titration protocols. The critical risk is that valproic acid significantly inhibits lamotrigine metabolism, requiring much slower titration (typically starting at 25 mg every other day) to prevent Stevens-Johnson Syndrome and toxic epidermal necrolysis. Option B is the BEST action because it addresses the safety concern through appropriate prescriber communication and ensures proper titration before dispensing a potentially dangerous dose. Option A is inadequate because simply counseling about rash doesn't prevent the serious reaction that can occur with improper dosing. Option C is inappropriate and illegal as therapeutic substitution requires prescriber authorization, and arbitrarily switching antiepileptic drugs could result in seizures. Option D is incorrect because taking with food doesn't prevent immunologic reactions like SJS/TEN, and proceeding with dispensing could result in a life-threatening reaction. The clinical pearl is that lamotrigine requires specific titration schedules that vary dramatically based on concurrent medications: slowest with valproic acid (enzyme inhibitor), standard alone, and fastest with enzyme inducers like carbamazepine.

Question 17

1. Continue the hospital-ordered warfarin 7.5 mg daily because higher doses are typical during acute infection
2. Discontinue amiodarone to reduce the INR and keep warfarin at 7.5 mg daily
3. Clarify the intended warfarin dose with the prescriber using the SNF record and current INR, and recommend holding/adjusting warfarin per protocol (correct answer)
4. Ignore the SNF medication list because it is often outdated and document only the hospital orders

Explanation: This question evaluates medication reconciliation skills for high-risk anticoagulants during care transitions. The critical risk factor is the discrepancy between the SNF warfarin dose (5 mg daily) and the hospital admission order (7.5 mg daily), combined with a supratherapeutic INR of 3.4. Option C is the BEST approach because it addresses the medication discrepancy through proper communication channels while prioritizing patient safety by recommending appropriate warfarin management based on the elevated INR. Option A is incorrect because continuing the higher warfarin dose with an already elevated INR could lead to serious bleeding complications, and infections typically increase (not decrease) warfarin requirements. Option B is inappropriate because abruptly discontinuing amiodarone won't immediately resolve the drug interaction, and unilateral medication changes without prescriber involvement are outside pharmacy scope. Option D is dangerous because ignoring facility medication lists during transitions is a major cause of medication errors and violates reconciliation standards. The transferable principle is that medication reconciliation requires comparing all medication sources, identifying discrepancies, and resolving them through prescriber communication, especially for high-alert medications like warfarin where dosing errors can be fatal.

Question 18

1. Baseline and periodic ophthalmologic retinal exams (per guideline intervals) and assessment for visual changes (correct answer)
2. INR every 2 weeks to monitor for bleeding risk from hydroxychloroquine
3. Serum troponin monthly to monitor for myocarditis from hydroxychloroquine
4. A1c every month to monitor for hydroxychloroquine-induced hyperglycemia

Explanation: This question evaluates risk management for adverse drug reactions through appropriate monitoring of hydroxychloroquine, focusing on its potential for ocular toxicity. The key patient-specific factor is the chronic use of hydroxychloroquine at 200 mg BID in a 67-year-old female reporting blurry vision, which signals possible retinopathy that can progress to irreversible vision loss if not detected early. Baseline and periodic ophthalmologic retinal exams per guideline intervals, along with assessing visual changes, is the best choice as it directly targets the primary risk of retinopathy, enabling timely discontinuation if toxicity is identified. Choice B is incorrect because hydroxychloroquine does not significantly affect coagulation, making frequent INR monitoring unnecessary and irrelevant to the main adverse event. Choices C and D are suboptimal as serum troponin is not indicated for routine myocarditis monitoring with this drug, and monthly A1c is inappropriate since hydroxychloroquine is more associated with hypoglycemia than hyperglycemia. A transferable clinical pearl is to prioritize drug-specific monitoring parameters based on evidence-based guidelines to prevent irreversible harms. In pharmacy practice, using decision frameworks like REMS protocols or patient risk stratification ensures proactive adverse event prevention and optimal therapeutic management.

Question 19

1. Implement tall-man lettering and require indication verification (diuretic vs antibiotic) with pharmacist review of dose/frequency before dispensing metolazone/metronidazole (correct answer)
2. Dispense metronidazole because infection is more urgent than edema
3. Ask the patient to choose which medication they prefer based on side effects
4. Store both medications in the same automated dispensing cabinet pocket to reduce picking time

Explanation: This question tests the concept of preventing look-alike/sound-alike (LASA) medication errors through system-based strategies in pharmacy dispensing workflows. The key risk element is the similarity between metolazone (a diuretic) and metronidazole (an antibiotic), compounded by the patient's existing diuretic therapy with furosemide and potential for harm from unnecessary antibiotic exposure in an elderly patient with elevated SCr. Implementing tall-man lettering (e.g., metOLAZONE vs metroNIDAZOLE) and requiring indication verification with pharmacist review of dose/frequency is the best choice as it directly addresses the LASA risk at multiple points, ensuring the correct medication is dispensed and preventing missed therapy or adverse effects like antibiotic resistance or interactions with warfarin. Choice B is incorrect because it assumes an infection exists when the prescription is for edema, leading to inappropriate dispensing and potential harm from unnecessary antibiotics without addressing the error root cause. Choices C and D are suboptimal as patient preference does not mitigate dispensing errors, and storing similar drugs together increases picking errors rather than reducing them. A key clinical pearl is to always employ multiple barriers like visual differentiation and double-checks for LASA drugs to enhance patient safety. In pharmacy practice, adopting frameworks like ISMP's targeted strategies for high-alert medications can systematically minimize errors and improve outcomes.

Question 20

1. Refill early if the patient pays cash and presents a photo ID
2. Dispense a partial supply now and dispense the remainder later without prescriber authorization
3. Decline the early refill and document the request; check the PDMP and contact the prescriber to determine if a replacement is appropriate (correct answer)
4. Transfer the oxycodone prescription to another pharmacy to avoid conflict and close the record

Explanation: This question addresses controlled substance diversion risk and regulatory compliance in community pharmacy practice. The key risk factors are the early refill request after only 10 days, the claim of a "lost" bottle, and the request to pay cash, which are classic red flags for potential diversion. Option C is the BEST response because it follows proper controlled substance protocols by declining the early refill, documenting the suspicious request, checking the Prescription Drug Monitoring Program (PDMP) for filling patterns, and involving the prescriber in determining whether a replacement is clinically appropriate. Option A is incorrect because simply accepting cash payment doesn't address the regulatory requirements or clinical appropriateness of an early opioid refill. Option B violates DEA regulations as partial fills of Schedule II medications require specific documentation and cannot be completed without proper authorization. Option D is inappropriate because transferring the prescription doesn't resolve the compliance issue and may enable doctor shopping or diversion. The clinical pearl is that pharmacists must balance patient care with regulatory compliance by using tools like PDMP checks, prescriber verification, and documentation to make informed decisions about early controlled substance refills while preventing diversion.